Vagifem 10 mikrogram vaginaltabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

vagifem 10 mikrogram vaginaltabletter

novo nordisk a/s - estradiolhemihydrat - vaginaltabletter - 10 mikrogram

Estrogel 0,6 mg/g Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

estrogel 0,6 mg/g

besins healthcare ireland limited - estradiol - gel - 0,6 mg/g

Senshio Den Europæiske Union - dansk - EMA (European Medicines Agency)

senshio

shionogi b.v. - ospemifen - menopausen - køn hormoner og modulatorer af den genitale system, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.

Ngenla Den Europæiske Union - dansk - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hypofysen og hypothalamus hormoner og analoger - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Ryeqo Den Europæiske Union - dansk - EMA (European Medicines Agency)

ryeqo

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyom - hypofysiske og hypotalamiske hormoner og analoger - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Fareston Den Europæiske Union - dansk - EMA (European Medicines Agency)

fareston

orion corporation - toremifen - bryst neoplasmer - endokrine terapi - første linjehormonbehandling af hormonafhængig metastatisk brystkræft hos postmenopausale patienter. fareston anbefales ikke til patienter med østrogen-receptor negative tumorer.

Sogroya Den Europæiske Union - dansk - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - vækst - hypofysiske og hypotalamiske hormoner og analoger - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).